{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:23:07Z","timestamp":1761060187008,"version":"3.40.5"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.critrevonc.2016.08.007","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T06:30:28Z","timestamp":1472020228000},"page":"119-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Prostate cancer perspectives after chaarted: Optimizing treatment sequence"],"prefix":"10.1016","volume":"107","author":[{"given":"Sergio V\u00e1zquez","family":"Est\u00e9vez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urbano Anido","family":"Herranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio Fern\u00e1ndez","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Javier","family":"Afonso Afonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda Santom\u00e9","family":"Couto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn L\u00e1zaro","family":"Quintela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Le\u00f3n","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1854-1051","authenticated-orcid":false,"given":"Sonia","family":"Maci\u00e1 Escalante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"March (3)","key":"10.1016\/j.critrevonc.2016.08.007_bib0005","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/14737140.2015.999045","article-title":"Radium-223 dichloride: a new paradigm in the treatment of prostate cancer","volume":"15","author":"Anido Herranz","year":"2015","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0010","unstructured":"A Study of Alpharadin\u00ae With Docetaxel in Patients With Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC). 2010. Available from: http:\/\/clinicaltrials.gov\/show\/NCT01106352."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0015","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01578655."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0020","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S0969-8043(97)00039-0","article-title":"Overview of nuclides for bone palliation","volume":"49","author":"Atkins","year":"1998","journal-title":"Appl. Radiat. Isot."},{"issue":"July (5)","key":"10.1016\/j.critrevonc.2016.08.007_bib0025","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0030","first-page":"682","article-title":"Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions","volume":"41","author":"Bouchet","year":"2000","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2016.08.007_bib0035","doi-asserted-by":"publisher","first-page":"36","DOI":"10.17925\/EOH.2012.08.01.36","article-title":"Docetaxel rechallenge in patients with castration-resistant prostate cancer \u2013 a review","volume":"8","author":"Caffo","year":"2012","journal-title":"Eur. Oncol. Haematol."},{"issue":"September","key":"10.1016\/j.critrevonc.2016.08.007_bib0040","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1200\/JCO.2009.26.8771","article-title":"Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer","author":"Chi","year":"2010","journal-title":"JCO"},{"issue":"Suppl. 4","key":"10.1016\/j.critrevonc.2016.08.007_bib0045","first-page":"iv255","article-title":"A randomized phase 3 study comparing first-line docetaxel\/prednisone (DP) to DP plus custirsen in men with metastatic castration-resistant prostate","volume":"25","author":"Chi","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0050","unstructured":"European Association of Urology. Prostate cancer guidelines, 2016."},{"issue":"April (6)","key":"10.1016\/j.critrevonc.2016.08.007_bib0055","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe:estimates for 40 countries in 2012","volume":"49","author":"Ferlay","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2016.08.007_bib0060","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol."},{"issue":"November (11)","key":"10.1016\/j.critrevonc.2016.08.007_bib0065","first-page":"2354","article-title":"Management of patients with advanced prostate cancer: recommendations of the St. Gallen advanced prostate cancer consensus conference (APCCC) 2015","volume":"26","author":"Gillesen","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0070","first-page":"21","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU 15","author":"Gravis","year":"2015","journal-title":"Trial Eur. Urol."},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2016.08.007_bib0075","article-title":"Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-na\u00efve metastatic prostate cancer (PCa): Long-term analysis of the GETUG-AFU 15 phase III trial","volume":"33","author":"Gravis","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"November (17)","key":"10.1016\/j.critrevonc.2016.08.007_bib0080","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1016\/j.ejca.2013.07.144","article-title":"Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy","volume":"49","author":"Harland","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"February (2)","key":"10.1016\/j.critrevonc.2016.08.007_bib0085","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EUA guidelines on prostate cancer Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.007_bib0090","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/cncr.23669","article-title":"Phase 1\/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer","volume":"113","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0095","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","author":"James","year":"2015","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2016.08.007_bib0100","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.007_bib0105","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1200\/JCO.2009.25.0597","article-title":"Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer","volume":"28","author":"Kantoff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0110","first-page":"688","article-title":"Radionuclides for metastatic bone pain palliation: a need for rational re-evaluation in the new millennium","volume":"41","author":"Krishnamurthy","year":"2000","journal-title":"J. Nucl. Med."},{"issue":"June (7)","key":"10.1016\/j.critrevonc.2016.08.007_bib0115","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0120","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1200\/JCO.2006.10.1949","article-title":"Initial hormonal management of androgen-sensitive metastatic, recurrent or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline","volume":"25","author":"Loblaw","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2016.08.007_bib0125","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1517\/13543780902997928","article-title":"Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer","volume":"18","author":"Madan","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0130","first-page":"1877","article-title":"Rhenium-196(Sn) HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"J. Nucl. Med."},{"issue":"June (3)","key":"10.1016\/j.critrevonc.2016.08.007_bib0135","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1053\/j.seminoncol.2013.04.008","article-title":"Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?","volume":"40","author":"Morris","year":"2013","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0140","unstructured":"NCCN Guidelines Version 1.2015 Prostate cancer."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0145","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Version 3.2016"},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0150","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.clgc.2012.07.002","article-title":"Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases","volume":"11","author":"Nilsson","year":"2013","journal-title":"Clin. Genitourin. Cancer"},{"issue":"November","key":"10.1016\/j.critrevonc.2016.08.007_bib0155","first-page":"6705","article-title":"Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer","volume":"1","author":"Okegawa","year":"2014","journal-title":"Anticancer Res."},{"issue":"July (3)","key":"10.1016\/j.critrevonc.2016.08.007_bib0160","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.007_bib0165","first-page":"vi106","article-title":"Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Parker","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0170","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and Estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer","volume":"351","author":"Petrylak","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0175","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1001\/jama.1995.03530050068035","article-title":"Strontium-89 therapy for the palliation of pain due to osseous metastases","volume":"274","author":"Robinson","year":"1995","journal-title":"JAMA"},{"issue":"January (2)","key":"10.1016\/j.critrevonc.2016.08.007_bib0180","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"June (7)","key":"10.1016\/j.critrevonc.2016.08.007_bib0185","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol."},{"issue":"suppl","key":"10.1016\/j.critrevonc.2016.08.007_bib0190","article-title":"Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): a three-arm phase III study (FIRSTANA)","volume":"34","author":"Sartor","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2016.08.007_bib0195","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0200","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using Samarium-153 lex-idronam: a double-blind placebo-controlled clinical trial","volume":"16","author":"Serafini","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"18S","key":"10.1016\/j.critrevonc.2016.08.007_bib0205","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1200\/jco.2006.24.18_suppl.4609","article-title":"Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0210","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.4609","article-title":"Randomized phase II study comparing 4 monthly doses of ipilimumab (MDX-010) as a single agent or in combination with a single dose of docetaxel in patients with hormone-refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2016.08.007_bib0215","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0220","first-page":"7","article-title":"A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)","author":"Small","year":"2009","journal-title":"Genitourinary Cancers Symposium"},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0225","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1200\/JCO.2012.45.0494","article-title":"Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial","volume":"31","author":"Smith","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 7","key":"10.1016\/j.critrevonc.2016.08.007_bib0230","article-title":"Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and\/or enzalutamide (E)","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0235","first-page":"61","article-title":"Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I\/II clinical study","volume":"4","author":"Srivastava","year":"1998","journal-title":"Clin. Cancer Res."},{"issue":"August (8)","key":"10.1016\/j.critrevonc.2016.08.007_bib0240","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-Sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.08.007_bib0245","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","author":"Vale","year":"2015","journal-title":"Lancet Oncol."},{"issue":"Suppl","key":"10.1016\/j.critrevonc.2016.08.007_bib0250","first-page":"5068","article-title":"Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who did or did not receive prior docetaxel (D) in the phase III ALSYMPCA trial","volume":"31","author":"Vogelzang","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816301846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T13:16:02Z","timestamp":1601039762000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816301846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":50,"alternative-id":["S1040842816301846"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate cancer perspectives after chaarted: Optimizing treatment sequence","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}